Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial
NCT07225387
This study is recruiting at 7 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase IV, open-label, randomized trial to determine whether the combination of Belimumab (BEL) and Voclosporin (VCS), plus background therapy with Mycophenolate Mofetil (MMF), improves the proportion of patients with proliferative lupus nephritis achieving complete renal response (CRR) compared to proportion of patients achieving CRR from recent clinical trials. This protocol will additionally determine whether combination therapy using Belimumab (BEL) and Voclosporin (VCS) facilitates rapid discontinuation of MMF.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Lupus Nephritis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- NephroNet, Inc.
- Last updated on ClinicalTrials.gov
- November 6, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- AARA Clinical Research · Glendale, AZ
Georgia · 3
- Piedmont Physicians Rheumatology · Atlanta, GA
- Georgia Nephrology Research Institute · Lawrenceville, GA
- Parris & Associates · Lawrenceville, GA
Ohio · 1
- Nephrology Clinical Trials Unit The Ohio State University Wexner Medical Center · Columbus, OH
Oklahoma · 1
- Oklahoma Medical Research Foundation · Oklahoma City, OK
Texas · 1
- AARA Clinical Research · Fort Worth, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.